Data protection Impressum

Life sciences

GeNeuro‘s mission is to leverage HERV biology to develop safe and effective treatments for the benefit of patients, by neutralizing causal factors encoded by HERVs that represent 8% of human DNA.

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments

5 February 2024

Onward Therapeutics’ move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments.

Onward Therapeutics enters clinical phase with innovative cancer immunotherapy

30 January 2024

This CHF 18 million initiative focuses on developing artificial intelligence-guided neuromodulation therapies to treat neurologic and mental health disorders.

Wyss Center launches Lighthouse Partnership with key institutions from Western Switzerland

29 January 2024

Founded in 2016 in Argentina, Stämm, now boasting a robust team of over 200 in Buenos Aires and San Francisco, specializes in harnessing nature-inspired, data-driven solutions to revolutionize bioprocessing.

Biomanufacturing innovator Stämm opens its European R&D facility in Monthey

25 January 2024

BioLizard’s move to Lausanne reflects its growing international presence and dedication to serving the Swiss biotech industry.

Bioinformatics specialist BioLizard opens a new office at the Biopôle in Lausanne

24 January 2024

This achievement, part of the PILATUS First-In-Human Clinical study (ClinicalTrials ID: NCT06119607), marks a new era in the field of valve replacement.

Novostia successfully implants its TRIFLO Heart Valve Implant in first human patient

24 January 2024

Timeline’s new funding round, led by BOLD (Business Opportunities for L’Oréal Development), includes strategic investments from industry giants L’Oréal and Nestlé.

Timeline secures CHF 56 million to propel its pioneering role in longevity and healthy aging

24 January 2024

Nicolas Collin, Co-Founder and CEO of the Vaccine Formulation Institute (VFI), discusses the innovative approach and global impact of their work in developing high-quality, accessible adjuvants for vaccines and why Geneva was chosen as the ideal location for VFI's impactful work.

Why the Vaccine Formulation Institute chose Western Switzerland

23 January 2024

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Cellestia Biotech receives CHF 2 million for its pioneering GvHD prevention therapy

23 January 2024

STALICLA has developed the first neurodevelopmental disorder-specific precision medicine platform with an initial application in autism spectrum disorder (ASD).

STALICLA secures USD 17.4 million to propel neuro precision medicine

22 January 2024

1 … 8 9 10 11 12 13 14 15 16 … 39